NDRG1

Last updated
NDRG1
Identifiers
Aliases NDRG1 , CAP43, CMT4D, DRG-1, DRG1, GC4, HMSNL, NDR1, NMSL, PROXY1, RIT42, RTP, TARG1, TDD5, N-myc downstream regulated 1
External IDs OMIM: 605262 MGI: 1341799 HomoloGene: 55953 GeneCards: NDRG1
Orthologs
SpeciesHumanMouse
Entrez

10397

17988

Ensembl

ENSG00000104419

ENSMUSG00000005125

UniProt

Q92597

Q62433

RefSeq (mRNA)

NM_008681

RefSeq (protein)

NP_032707

Location (UCSC) Chr 8: 133.24 – 133.3 Mb Chr 15: 66.8 – 66.84 Mb
PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

Protein NDRG1 is a protein that in humans is encoded by the NDRG1 gene. [5] [6] [7] [8]

Contents

This gene is a member of the N-myc downregulated gene family which belongs to the alpha/beta hydrolase superfamily. The protein encoded by this gene is a cytoplasmic protein involved in stress responses, hormone responses, cell growth, and differentiation [ citation needed ]. Mutations in this gene have been reported to be causative the autosomal-recessive version of Charcot-Marie-Tooth disease known as CMT4D. [8]

It has been reported that NDRG1 localizes to the endosomes and is a Rab4a effector involved in vesicular recycling. [9]

As reviewed by Fang et al., [10] NDRG1 is involved in embryogenesis and development, cell growth and differentiation, lipid biosynthesis and myelination, stress responses, immunity, DNA repair and cell adhesion among other functions. NDRG1 is localised in the cytoplasm, nucleus and mitochondrion, at probabilities of 47.8%, 26.1% and 8.7%, respectively. In response to DNA damage NDRG1 translocates from the cytoplasm to the nucleus, where it may inhibit cell growth and promote DNA repair mechanisms. It is suggested that NDRG1 acts as a stress response gene or potentially as a transcription factor.

Gene

In humans, NDRG1 gene is located on the long arm of chromosome 8 (8q24.22). The gene encodes a 3.0 kilobases (kb) messenger RNA (mRNA) composed of 394 amino acids. NDRG1 belong to the NDRG1 family consisting of four members - NDRG1, NDRG2, NDRG3 and NDRG4 - that share a 53-65 % homology. In contrast to other family members, NDRG1 has a three tandem (GTRSRSHTSE) repeats in the C-terminal part. [11] [12]

The expression of NDRG1 is regulated by hypoxia dependent and independent manner. Under hypoxia the oxygen sensor hypoxia-inducible factor (HIF)-1α is translocated from cytoplasma to nucleus, where binds to HIF-1β to form HIF-1 complex. This complex works as a transcription factor, binds to hypoxia response element (HRE) in the promoter of hypoxia-related genes, one of these genes is the NDRG1. [13] Also heavy metal ions (nickel, cobalt, iron) upregulate NDRG1 by mimicking hypoxia. Opposite effect on NDRG1 expression could have myc oncoproteins, N-myc and c-myc, which transcriptionally repress the expression. These effect is mediated indirectly by decreasing its promoter activity. [10]

Role in cancer

As reviewed by Kovacevic et al., [14] NDRG1 is a potent, iron-regulated growth and metastasis suppressor that was found to be negatively correlated with cancer progression in a number of tumors, including prostate, pancreatic, breast, and colon cancers. NDRG1 has marked anti-oncogenic activity, being associated with decreased cell proliferation, migration, invasion, and angiogenesis. The molecular functions of NDRG1 affect numerous signaling pathways that regulate cancer cell proliferation, invasion, angiogenesis, and migration. Specifically, NDRG1 inhibits the oncogenic RAS, c-Src, phosphatidylinositol 3-kinase (PI3K), WNT, ROCK1/pMLC2, and nuclear factor-light chain enhancer of activated B cell (NF-B) pathways, while promoting expression of key tumor-suppressive molecules including phosphatase and tensin homolog, E-cadherin, and mothers against decapentaplegic homolog 4 (SMAD4). Through its effects on E-cadherin and beta-catenin, which form the adherens junction and promote cell adhesion, NDRG1 also inhibits the epithelial to mesenchymal transition, an initial key step in metastasis.

Functions in DNA repair and aging

In one of its functions at a molecular level, NDRG1 binds and stabilizes methyltransferases, chiefly O-6-methylguanine-DNA methyltransferase (MGMT), [15] a DNA repair protein. Thus, higher expression of NDRG1 can promote MGMT protein stability and activity. Dominick et al. [16] showed NDRG1 and MGMT protein expression was increased by 2-fold to 3-fold for each of three strains of mice (Snell, GHKRO, and PAPPA-KO) with increased longevity. These authors strongly suggest a link between the increase in the MGMT DNA repair pathway and a delay in the aging process in these mouse strains. This is consistent with the DNA damage theory of aging.

Role in immune system

The NDRG1 plays an important role in allergy and anaphylaxis, defence against bacterial pathogens and bacterial clearance, inflammation and wound healing. In mast cells, NDRG1 is upregulated during maturation and helps to rapid degranulation, which leads to enhanced exocytosis in response to various stimuli. [17] Also was shown its role in T-cell clonal anergy downstream of Egr2, where NDRG1 is upregulated in the absence of costimulation to inhibit subsequent re-activation of T cells by TCR and CD28 signalling. [18]

Related Research Articles

<span class="mw-page-title-main">Oncogene</span> Gene that has the potential to cause cancer

An oncogene is a gene that has the potential to cause cancer. In tumor cells, these genes are often mutated, or expressed at high levels.

p53 Mammalian protein found in Homo sapiens

p53, also known as Tumor protein P53, cellular tumor antigen p53, or transformation-related protein 53 (TRP53) is a regulatory protein that is often mutated in human cancers. The p53 proteins are crucial in vertebrates, where they prevent cancer formation. As such, p53 has been described as "the guardian of the genome" because of its role in conserving stability by preventing genome mutation. Hence TP53 is classified as a tumor suppressor gene.

<span class="mw-page-title-main">Tumor hypoxia</span> Situation where tumor cells have been deprived of oxygen

Tumor hypoxia is the situation where tumor cells have been deprived of oxygen. As a tumor grows, it rapidly outgrows its blood supply, leaving portions of the tumor with regions where the oxygen concentration is significantly lower than in healthy tissues. Hypoxic microenvironements in solid tumors are a result of available oxygen being consumed within 70 to 150 μm of tumour vasculature by rapidly proliferating tumor cells thus limiting the amount of oxygen available to diffuse further into the tumor tissue. In order to support continuous growth and proliferation in challenging hypoxic environments, cancer cells are found to alter their metabolism. Furthermore, hypoxia is known to change cell behavior and is associated with extracellular matrix remodeling and increased migratory and metastatic behavior.

Hypoxia-inducible factors (HIFs) are transcription factors that respond to decreases in available oxygen in the cellular environment, or hypoxia.

<span class="mw-page-title-main">Von Hippel–Lindau tumor suppressor</span> Mammalian protein found in Homo sapiens

The Von Hippel–Lindau tumor suppressor also known as pVHL is a protein that, in humans, is encoded by the VHL gene. Mutations of the VHL gene are associated with Von Hippel–Lindau disease, which is characterized by hemangioblastomas of the brain, spinal cord and retina. It is also associated with kidney and pancreatic lesions.

Myc is a family of regulator genes and proto-oncogenes that code for transcription factors. The Myc family consists of three related human genes: c-myc (MYC), l-myc (MYCL), and n-myc (MYCN). c-myc was the first gene to be discovered in this family, due to homology with the viral gene v-myc.

Stem-cell niche refers to a microenvironment, within the specific anatomic location where stem cells are found, which interacts with stem cells to regulate cell fate. The word 'niche' can be in reference to the in vivo or in vitro stem-cell microenvironment. During embryonic development, various niche factors act on embryonic stem cells to alter gene expression, and induce their proliferation or differentiation for the development of the fetus. Within the human body, stem-cell niches maintain adult stem cells in a quiescent state, but after tissue injury, the surrounding micro-environment actively signals to stem cells to promote either self-renewal or differentiation to form new tissues. Several factors are important to regulate stem-cell characteristics within the niche: cell–cell interactions between stem cells, as well as interactions between stem cells and neighbouring differentiated cells, interactions between stem cells and adhesion molecules, extracellular matrix components, the oxygen tension, growth factors, cytokines, and the physicochemical nature of the environment including the pH, ionic strength and metabolites, like ATP, are also important. The stem cells and niche may induce each other during development and reciprocally signal to maintain each other during adulthood.

<span class="mw-page-title-main">HIF1A</span> Protein-coding gene in the species Homo sapiens

Hypoxia-inducible factor 1-alpha, also known as HIF-1-alpha, is a subunit of a heterodimeric transcription factor hypoxia-inducible factor 1 (HIF-1) that is encoded by the HIF1A gene. The Nobel Prize in Physiology or Medicine 2019 was awarded for the discovery of HIF.

<span class="mw-page-title-main">MTA1</span> Protein-coding gene in the species Homo sapiens

Metastasis-associated protein MTA1 is a protein that in humans is encoded by the MTA1 gene. MTA1 is the founding member of the MTA family of genes. MTA1 is primarily localized in the nucleus but also found to be distributed in the extra-nuclear compartments. MTA1 is a component of several chromatin remodeling complexes including the nucleosome remodeling and deacetylation complex (NuRD). MTA1 regulates gene expression by functioning as a coregulator to integrate DNA-interacting factors to gene activity. MTA1 participates in physiological functions in the normal and cancer cells. MTA1 is one of the most upregulated proteins in human cancer and associates with cancer progression, aggressive phenotypes, and poor prognosis of cancer patients.

<span class="mw-page-title-main">EGLN1</span> Protein-coding gene in the species Homo sapiens

Hypoxia-inducible factor prolyl hydroxylase 2 (HIF-PH2), or prolyl hydroxylase domain-containing protein 2 (PHD2), is an enzyme encoded by the EGLN1 gene. It is also known as Egl nine homolog 1. PHD2 is a α-ketoglutarate/2-oxoglutarate-dependent hydroxylase, a superfamily non-haem iron-containing proteins. In humans, PHD2 is one of the three isoforms of hypoxia-inducible factor-proline dioxygenase, which is also known as HIF prolyl-hydroxylase.

<span class="mw-page-title-main">NDRG2</span> Protein-coding gene in humans

Protein NDRG2 is a protein that in humans is encoded by the NDRG2 gene.

<span class="mw-page-title-main">STAU1</span> Protein-coding gene in the species Homo sapiens

Double-stranded RNA-binding protein Staufen homolog 1 is a protein that in humans is encoded by the STAU1 gene.

<span class="mw-page-title-main">ID4</span> Protein-coding gene in humans

ID4 is a protein coding gene. In humans, it encodes for the protein known as DNA-binding protein inhibitor ID-4. This protein is known to be involved in the regulation of many cellular processes during both prenatal development and tumorigenesis. This is inclusive of embryonic cellular growth, senescence, cellular differentiation, apoptosis, and as an oncogene in angiogenesis.

<span class="mw-page-title-main">MTSS1</span> Protein-coding gene in the species Homo sapiens

Metastasis suppressor protein 1 is a protein that in humans is encoded by the MTSS1 gene. True to its name, it codes for a metastasis suppressor.

<span class="mw-page-title-main">MTA3</span> Protein-coding gene in the species Homo sapiens

Metastasis-associated protein MTA3 is a protein that in humans is encoded by the MTA3 gene. MTA3 protein localizes in the nucleus as well as in other cellular compartments MTA3 is a component of the nucleosome remodeling and deacetylate (NuRD) complex and participates in gene expression. The expression pattern of MTA3 is opposite to that of MTA1 and MTA2 during mammary gland tumorigenesis. However, MTA3 is also overexpressed in a variety of human cancers.

<span class="mw-page-title-main">SDPR</span> Protein-coding gene in the species Homo sapiens

Cavin-2 or Serum deprivation-response protein (SDPR) is a protein that in humans is encoded by the SDPR gene. Cavin-2 is highly expressed in a variety of human endothelial cells.

<span class="mw-page-title-main">MTDH</span> Protein-coding gene in the species Homo sapiens

Metadherin, also known as protein LYRIC or astrocyte elevated gene-1 protein (AEG-1) is a protein that in humans is encoded by the MTDH gene.

<span class="mw-page-title-main">BHLHE41</span> Protein-coding gene in humans

"Basic helix-loop-helix family, member e41", or BHLHE41, is a gene that encodes a basic helix-loop-helix transcription factor repressor protein in various tissues of both humans and mice. It is also known as DEC2, hDEC2, and SHARP1, and was previously known as "basic helix-loop-helix domain containing, class B, 3", or BHLHB3. BHLHE41 is known for its role in the circadian molecular mechanisms that influence sleep quantity as well as its role in immune function and the maturation of T helper type 2 cell lineages associated with humoral immunity.

<span class="mw-page-title-main">Cancer epigenetics</span> Field of study in cancer research

Cancer epigenetics is the study of epigenetic modifications to the DNA of cancer cells that do not involve a change in the nucleotide sequence, but instead involve a change in the way the genetic code is expressed. Epigenetic mechanisms are necessary to maintain normal sequences of tissue specific gene expression and are crucial for normal development. They may be just as important, if not even more important, than genetic mutations in a cell's transformation to cancer. The disturbance of epigenetic processes in cancers, can lead to a loss of expression of genes that occurs about 10 times more frequently by transcription silencing than by mutations. As Vogelstein et al. points out, in a colorectal cancer there are usually about 3 to 6 driver mutations and 33 to 66 hitchhiker or passenger mutations. However, in colon tumors compared to adjacent normal-appearing colonic mucosa, there are about 600 to 800 heavily methylated CpG islands in the promoters of genes in the tumors while these CpG islands are not methylated in the adjacent mucosa. Manipulation of epigenetic alterations holds great promise for cancer prevention, detection, and therapy. In different types of cancer, a variety of epigenetic mechanisms can be perturbed, such as the silencing of tumor suppressor genes and activation of oncogenes by altered CpG island methylation patterns, histone modifications, and dysregulation of DNA binding proteins. There are several medications which have epigenetic impact, that are now used in a number of these diseases.

References

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000104419 - Ensembl, May 2017
  2. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000005125 - Ensembl, May 2017
  3. ↑ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ↑ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ↑ van Belzen N, Dinjens WN, Diesveld MP, Groen NA, van der Made AC, Nozawa Y, et al. (July 1997). "A novel gene which is up-regulated during colon epithelial cell differentiation and down-regulated in colorectal neoplasms". Laboratory Investigation; A Journal of Technical Methods and Pathology. 77 (1): 85–92. PMID   9251681.
  6. ↑ Kokame K, Kato H, Miyata T (November 1996). "Homocysteine-respondent genes in vascular endothelial cells identified by differential display analysis. GRP78/BiP and novel genes". The Journal of Biological Chemistry. 271 (47): 29659–65. doi: 10.1074/jbc.271.47.29659 . PMID   8939898.
  7. ↑ Zhang J, Chen S, Zhang W, Zhang J, Liu X, Shi H, et al. (July 2008). "Human differentiation-related gene NDRG1 is a Myc downstream-regulated gene that is repressed by Myc on the core promoter region". Gene. 417 (1–2): 5–12. doi:10.1016/j.gene.2008.03.002. PMID   18455888.
  8. 1 2 "Entrez Gene: NDRG1 N-myc downstream regulated gene 1".
  9. ↑ Kachhap SK, Faith D, Qian DZ, Shabbeer S, Galloway NL, Pili R, et al. (September 2007). Heisenberg C (ed.). "The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin". PLOS ONE. 2 (9): e844. Bibcode:2007PLoSO...2..844K. doi: 10.1371/journal.pone.0000844 . PMC   1952073 . PMID   17786215. Open Access logo PLoS transparent.svg
  10. 1 2 Fang BA, Kovačević Ž, Park KC, Kalinowski DS, Jansson PJ, Lane DJ, et al. (January 2014). "Molecular functions of the iron-regulated metastasis suppressor, NDRG1, and its potential as a molecular target for cancer therapy". Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1845 (1): 1–19. doi:10.1016/j.bbcan.2013.11.002. PMID   24269900.
  11. ↑ Sahni S, Park KC, Kovacevic Z, Richardson DR (June 2019). "Two mechanisms involving the autophagic and proteasomal pathways process the metastasis suppressor protein, N-myc downstream regulated gene 1". Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1865 (6): 1361–1378. doi:10.1016/j.bbadis.2019.02.008. PMID   30763642. S2CID   73439295.
  12. ↑ Sun J, Zhang D, Bae DH, Sahni S, Jansson P, Zheng Y, et al. (September 2013). "Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors". Carcinogenesis. 34 (9): 1943–54. doi: 10.1093/carcin/bgt163 . PMID   23671130.
  13. ↑ Park KC, Paluncic J, Kovacevic Z, Richardson DR (May 2019). "Pharmacological targeting and the diverse functions of the metastasis suppressor, NDRG1, in cancer". Free Radical Biology & Medicine. 157: 154–175. doi:10.1016/j.freeradbiomed.2019.05.020. PMID   31132412. S2CID   167220979.
  14. ↑ Kovacevic Z, Menezes SV, Sahni S, Kalinowski DS, Bae DH, Lane DJ, Richardson DR (January 2016). "The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways". The Journal of Biological Chemistry. 291 (3): 1029–52. doi: 10.1074/jbc.M115.689653 . PMC   4714189 . PMID   26534963.
  15. ↑ Weiler M, Blaes J, Pusch S, Sahm F, Czabanka M, Luger S, et al. (January 2014). "mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy". Proceedings of the National Academy of Sciences of the United States of America. 111 (1): 409–14. Bibcode:2014PNAS..111..409W. doi: 10.1073/pnas.1314469111 . PMC   3890826 . PMID   24367102.
  16. ↑ Dominick G, Bowman J, Li X, Miller RA, Garcia GG (February 2017). "mTOR regulates the expression of DNA damage response enzymes in long-lived Snell dwarf, GHRKO, and PAPPA-KO mice". Aging Cell. 16 (1): 52–60. doi:10.1111/acel.12525. PMC   5242303 . PMID   27618784.
  17. ↑ Kovacevic Z, Richardson DR (December 2006). "The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer". Carcinogenesis. 27 (12): 2355–66. doi:10.1093/carcin/bgl146. PMID   16920733.
  18. ↑ Oh YM, Park HB, Shin JH, Lee JE, Park HY, Kho DH, et al. (October 2015). "Ndrg1 is a T-cell clonal anergy factor negatively regulated by CD28 costimulation and interleukin-2". Nature Communications. 6 (1): 8698. Bibcode:2015NatCo...6.8698O. doi:10.1038/ncomms9698. PMC   4846325 . PMID   26507712.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.